Actavis Confirms Forest Labs (FRX) Acquisition

Actavis Plc (ACT), the world’s second-largest generic-drug maker by market value, confirmed early Tuesday it will buy the New York-based pharmaceutical firm Forest Laboratories Inc. (FRX) for about $25 billion. Under the agreement, Forest shareholders will get $89.48 per share, with $26.04 in cash and 0.3306 Actavis shares for each common stock they hold. The […] View the full post at: Actavis Confirms Forest Labs (FRX) Acquisition Related posts: FDA Panel Votes in Favor of Effectiveness of Forest Labs’ Daxas US panel rejects Forest, Nycomed lung drug Warner Chilcott to Announce a $3B Acquisition of Procter & Gamble’s Drug Unit